Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | SDHB | P21912 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13125431 | 0.83 | HSP90AA1 (0.57) | CYP2C19P2RY12HSP90AA1CYP1A2KEAP1 | |
| SCHEMBL9621580 | 0.83 | P2RY12 (0.64) | CYP2C19P2RY12HSP90AA1CYP1A2KEAP1 | |
| SCHEMBL10993472 | 0.75 | CYP2C19 (0.48) | CYP2C19P2RY12HSP90AA1CYP1A2KEAP1 | |
| SCHEMBL10986666 | 0.74 | CYP2C19 (0.46) | CYP2C19P2RY12HSP90AA1CYP1A2KEAP1 | |
| SCHEMBL9804556 | 0.71 | CYP2C19 (0.52) | CYP2C19P2RY12HSP90AA1CYP1A2KEAP1 | |
| SCHEMBL5891451 | 0.71 | HSP90AA1 (0.58) | PTGS2HSP90AA1HSP90AB1KDM4EHSD17B10 | |
| SCHEMBL9938291 | 0.71 | P2RY12 (0.53) | CYP2C19P2RY12HSP90AA1CYP1A2KEAP1 | |
| SCHEMBL3057367 | 0.70 | PKM (0.46) | CYP2C19P2RY12PTGS2SDHBPTGS1 | |
| SCHEMBL11904550 | 0.69 | MEN1 (0.47) | CYP2C19PTGS2SDHBCYP1A2PTGS1 | |
| SCHEMBL7806822 | 0.68 | HSP90AA1 (0.53) | PTGS2HSP90AA1HSP90AB1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| EP-1470122-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1470122-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20050209261-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2005-09-22 | — | — | US | disclosed |
| US-6943172-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050192304-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2005-09-01 | — | — | US | disclosed |
| US-6924290-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | BAYER CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-20040002507-A1 | Rho-kinase inhibitors | BAYER CORPORATION (US) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002507-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | CYP2C19 1525/4885P2RY12 4367/4885PTGS2 688/4885 |
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | CYP2C19 1525/4885P2RY12 4367/4885PTGS2 688/4885 |
| US-20050209261-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | CYP2C19 1525/4885P2RY12 4367/4885PTGS2 688/4885 |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | CIT, ROCK1, RHOT2 | CYP2C19 1383/4885P2RY12 4436/4885PTGS2 1424/4885 |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | CYP2C19 1525/4885P2RY12 4367/4885PTGS2 688/4885 |
| US-20050192304-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | CYP2C19 1525/4885P2RY12 4367/4885PTGS2 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.